Kadmon Holdings Inc (KDMN) Stock
KDMN is no longer traded. Kadmon Holdings was acquired by Sanofi (SNY) on November 9, 2021.
Each KDMN share was exchanged for $9.50 in cash. Prices on this page are historical; the last trade was November 8, 2021 at $9.50.
See Sanofi (SNY) stock →Kadmon Holdings stock price history
KDMN final trading statistics
- Final close
- $9.50
- Final trading day
- Nov 8, 2021
- Market cap at delisting
- $1.70B
- Shares outstanding
- 178.52M
- Final 52-week range
- $3.19 – $9.50
- Avg. volume (final 3 mo.)
- 9,823,166
- All-time high (split-adj.)
- $10.23 · Aug 2016
- All-time low (split-adj.)
- $1.65 · Jun 2019
- Return since IPO
- -2.1%
- Beta
- 1.12
- Book value / share
- $0.08
- Price / book
- 115.85
Kadmon Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $8.29M | -$108.9M | -$0.68 |
| FY2019 | $5.09M | -$61.4M | -$0.49 |
| FY2018 | $1.40M | -$54.3M | -$0.53 |
| FY2017 | $12.26M | -$79.8M | -$1.49 |
| FY2016 | $26.05M | -$208.8M | -$5.54 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kadmon Holdings Inc
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. As of November 9, 2021, Kadmon Holdings, Inc. operates as a subsidiary of Sanofi.
Kadmon Holdings stock FAQ
What happened to Kadmon Holdings stock?
Kadmon Holdings was acquired by Sanofi (SNY) on November 9, 2021. Shareholders received $9.50 in cash for each share. KDMN stock stopped trading on the Nasdaq, with a final close of $9.50 on November 8, 2021.
What did Kadmon Holdings shareholders receive?
Each KDMN share was converted into $9.50 in cash. The deal was valued at about $1.9 billion.
Is KDMN stock still trading?
No. KDMN was delisted from the Nasdaq on November 9, 2021 and no longer trades on a U.S. exchange.
What was the last price of KDMN stock?
KDMN closed at $9.50 on its final trading day, November 8, 2021, for a market value of about $1.70B.
What were Kadmon Holdings's revenue and earnings in its last full fiscal year?
Kadmon Holdings reported revenue of $8.29M and net income of -$108.9M in fiscal 2020, its last full year as a public company.
When did Kadmon Holdings go public?
Kadmon Holdings Inc stock began trading on July 27, 2016.